RAS isoforms and mutations in cancer at a glance

Area of Science:

• Molecular Biology
• Cellular Signaling
• Oncology

Background:

• RAS proteins (KRAS4A, KRAS4B, NRAS, HRAS) act as molecular switches regulating critical cellular processes.
• Gain-of-function mutations in RAS genes are implicated in approximately 25% of human cancers.
• Despite extensive research, no anti-RAS therapies have achieved clinical success.

Purpose of the Study:

• To highlight the functional distinctions between RAS isoforms.
• To underscore the mutation-specific consequences of RAS alterations in cancer.
• To review the current landscape of anti-RAS drug discovery.

Main Methods:

• Comparative analysis of RAS protein isoforms.
• Review of cancer-associated RAS mutations and their biochemical impacts.
• Survey of ongoing anti-RAS therapeutic strategies.

Main Results:

• The four human RAS proteins exhibit distinct biological functions.
• Over 130 unique missense mutations exist in cancer, each with specific effects on RAS.
• Targeting RAS requires mutation-specific approaches due to isoform and mutation heterogeneity.

Conclusions:

• Understanding RAS isoform and mutation diversity is crucial for developing effective cancer treatments.
• Future anti-RAS therapies must be tailored to specific RAS mutations.
• Addressing RAS complexity is key to overcoming past therapeutic failures.